AAMU
XENE icon

Amundi Asset Management US’s Xenon Pharmaceuticals XENE Stock Holding History

Amundi Asset Management US’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,200
Closed -$148K – 1671
2018
Q3 		$148K Buy
+11,200
New +$130K ﹤0.01% 1487

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Amundi Asset Management US's XENE Position: Q4 2018 in Review

Amundi Asset Management US sold out of Xenon Pharmaceuticals (XENE) in Q4 2018, closing a stake of 11,200 shares — an estimated $148K sold.

Amundi Asset Management US first reported a position in XENE in Q3 2018 and held it in 1 quarter. The position peaked at $148K in Q3 2018. 58 funds tracked by Wall St. Rank hold XENE as of Q4 2018.

  • Amundi Asset Management US reported no remaining Xenon Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 11,200 Xenon Pharmaceuticals shares in Q4 2018, an estimated $148K.
  • Amundi Asset Management US first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Amundi Asset Management US's Xenon Pharmaceuticals position peaked at $148K in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.